About GlaxoSmithKline PLC (NYSE:GSK)
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSE:GSK
- CUSIP: N/A
- Web: www.gsk.com
Capitalization:- Market Cap: $100.41388 billion
- Outstanding Shares: 2,444,000,000
Average Prices:- 50 Day Moving Avg: $40.46
- 200 Day Moving Avg: $41.54
- 52 Week Range: $37.20 - $44.54
P/E:- Trailing P/E Ratio: 39.74
- Foreward P/E Ratio: 14.09
- P/E Growth: 1.24
Sales & Book Value:- Annual Revenue: $39.37 billion
- Price / Sales: 2.55
- Book Value: $0.44 per share
- Price / Book: 93.20
Dividend:- Annual Dividend: $1.98
- Dividend Yield: 4.9%
Profitability:- EBITDA: $10.76 billion
- Net Margins: 6.48%
- Return on Equity: 114.93%
- Return on Assets: 9.25%
Debt:- Debt-to-Equity Ratio: 2.77%
- Current Ratio: 0.57%
- Quick Ratio: 0.37%
Misc:- Average Volume: 3.13 million shs.
- Beta: 1.03
- Short Ratio: 1.71
Frequently Asked Questions for GlaxoSmithKline PLC (NYSE:GSK)
What is GlaxoSmithKline PLC's stock symbol?
GlaxoSmithKline PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
How often does GlaxoSmithKline PLC pay dividends? What is the dividend yield for GlaxoSmithKline PLC?
GlaxoSmithKline PLC announced a quarterly dividend on Wednesday, July 26th. Investors of record on Friday, August 11th will be paid a dividend of $0.491 per share on Thursday, October 12th. This represents a $1.96 dividend on an annualized basis and a yield of 4.79%. The ex-dividend date of this dividend is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC's previous quarterly dividend of $0.46. View GlaxoSmithKline PLC's Dividend History.
How were GlaxoSmithKline PLC's earnings last quarter?
GlaxoSmithKline PLC (NYSE:GSK) released its quarterly earnings data on Wednesday, July, 26th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.02. The firm earned $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. View GlaxoSmithKline PLC's Earnings History.
When will GlaxoSmithKline PLC make its next earnings announcement?
Where is GlaxoSmithKline PLC's stock going? Where will GlaxoSmithKline PLC's stock price be in 2017?
15 equities research analysts have issued 12-month price targets for GlaxoSmithKline PLC's shares. Their forecasts range from $37.00 to $50.00. On average, they anticipate GlaxoSmithKline PLC's share price to reach $43.50 in the next twelve months. View Analyst Ratings for GlaxoSmithKline PLC.
Who are some of GlaxoSmithKline PLC's key competitors?
Some companies that are related to GlaxoSmithKline PLC include Merck & Company (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX) and Taro Pharmaceutical Industries (TARO).
Who are GlaxoSmithKline PLC's key executives?
GlaxoSmithKline PLC's management team includes the folowing people:
- Emma Walmsley, Chief Executive Officer - Designate, Executive Director
- Simon Dingemans, Chief Financial Officer, Executive Director
- Patrick Vallance, President - Pharmaceuticals R&D, Executive Director
- Roger Connor, President - Global Manufacturing & Supply
- Abbas Hussain, President - Global Pharmaceuticals
- Shah Abbas Hussain, President - Global Pharmaceuticals
- Luke Miels, President - Global Pharmaceuticals
- Daniel E Troy, Senior Vice President, General Counsel
- Claire Thomas, Senior Vice President - Human Resources
- Nick Hirons, Senior Vice President – Global Ethics and Compliance
Who owns GlaxoSmithKline PLC stock?
Who bought GlaxoSmithKline PLC stock? Who is buying GlaxoSmithKline PLC stock?
How do I buy GlaxoSmithKline PLC stock?
Shares of GlaxoSmithKline PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlaxoSmithKline PLC's stock price today?
One share of GlaxoSmithKline PLC stock can currently be purchased for approximately $41.01.
MarketBeat Community Rating for GlaxoSmithKline PLC (NYSE GSK)MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 6 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.33) |
| Consensus Price Target: | $43.50 (6.07% upside) |
Consensus Price Target History for GlaxoSmithKline PLC (NYSE:GSK)
Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/18/2017 | J P Morgan Chase & Co | Reiterated Rating | Neutral | | N/A |  |
| 9/8/2017 | Morgan Stanley | Downgrade | Equal Weight -> Underweight | | Low | |
| 8/31/2017 | Argus | Reiterated Rating | Buy | $50.00 | Low | |
| 7/27/2017 | Citigroup Inc. | Reiterated Rating | Neutral | | Low | |
| 5/26/2017 | Berenberg Bank | Upgrade | Hold -> Buy | | Low | |
| 4/6/2017 | BNP Paribas | Lower Price Target | | $37.00 | Low | |
| 4/5/2017 | Exane BNP Paribas | Upgrade | Underperform -> Neutral | | Low | |
| 3/9/2017 | Liberum Capital | Initiated Coverage | Buy -> Buy | | Low | |
| 3/9/2017 | Kepler Capital Markets | Initiated Coverage | Reduce -> Reduce | | Low | |
| 3/7/2017 | Barclays PLC | Initiated Coverage | Equal Weight | | N/A | |
| 2/19/2017 | Jefferies Group LLC | Reiterated Rating | Buy | | N/A | |
| 2/9/2017 | Deutsche Bank AG | Reiterated Rating | Neutral | | N/A | |
| 12/27/2016 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Buy | | N/A | |
| 10/26/2016 | Beaufort Securities | Reiterated Rating | Buy | | N/A | |
| 10/20/2016 | Investec | Initiated Coverage | Buy | | N/A | |
| 9/23/2016 | Piper Jaffray Companies | Initiated Coverage | Overweight | | N/A | |
| 9/20/2016 | Bank of America Corporation | Reiterated Rating | Buy | $50.00 | N/A | |
| 9/12/2016 | HSBC Holdings plc | Reiterated Rating | Buy | | N/A | |
| 8/17/2016 | Shore Capital | Reiterated Rating | Hold | | N/A | |
| 5/26/2016 | Cowen and Company | Downgrade | Outperform -> Market Perform | | N/A | |
| 5/5/2016 | Oddo Securities | Upgrade | Reduce -> Buy | | N/A | |
| 2/26/2016 | Cantor Fitzgerald | Initiated Coverage | Hold | | N/A | |
| 2/4/2016 | Sanford C. Bernstein | Boost Price Target | Market Perform | $43.00 -> $45.00 | N/A | |
| 1/27/2016 | Bryan, Garnier & Co | Upgrade | Neutral -> Buy | | N/A | |
| 12/21/2015 | Leerink Swann | Reiterated Rating | Market Perform | $48.00 | N/A | |
| 10/31/2015 | Societe Generale | Reiterated Rating | Sell | | N/A | |
| 10/20/2015 | Credit Suisse Group | Upgrade | Underperform -> Neutral | | N/A | |
(Data available from 10/19/2015 forward)
Earnings History for GlaxoSmithKline PLC (NYSE:GSK)Earnings History by Quarter for GlaxoSmithKline PLC (NYSE GSK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | $0.82 | | | | | N/A | |
| 7/26/2017 | 6/30/2017 | $0.68 | $0.70 | $9.52 billion | $9.36 billion | View | N/A | |
| 4/26/2017 | 3/31/2017 | $0.62 | $0.62 | $9.09 billion | $9.23 billion | View | N/A | |
| 2/8/2017 | 12/31/2016 | $0.57 | $0.65 | $9.21 billion | $9.43 billion | View | Listen | |
| 10/26/2016 | Q316 | $0.77 | $0.83 | $8.92 billion | $9.90 billion | View | Listen | |
| 10/28/2015 | Q3 | $0.60 | $0.71 | $6.07 billion | $6.13 billion | View | N/A | |
| 7/29/2015 | Q215 | $0.50 | $0.53 | $9.14 billion | $9.02 billion | View | N/A | |
| 5/6/2015 | Q115 | $0.55 | $0.48 | $8.55 billion | $8.51 billion | View | N/A | |
| 2/4/2015 | Q414 | $0.86 | $0.82 | $6.14 billion | $6.19 billion | View | N/A | |
| 10/22/2014 | Q314 | $0.79 | $0.90 | $9.76 billion | $9.12 billion | View | Listen | |
| 7/23/2014 | Q114 | $0.71 | $0.65 | $10.13 billion | $9.47 billion | View | N/A | |
| 4/30/2014 | Q413 | $0.72 | $0.70 | $10.36 billion | $9.44 billion | View | N/A | |
| 2/5/2014 | Q4 | $0.30 | $0.30 | $6.84 billion | $6.91 billion | View | N/A | |
| 10/23/2013 | Q313 | | $0.31 | $10.31 billion | $10.09 billion | View | N/A | |
| 7/24/2013 | | $0.26 | $0.26 | | $6.62 billion | View | N/A | |
| 4/25/2012 | | $0.29 | $0.27 | | | View | N/A | |
| 2/7/2012 | | $0.30 | $0.28 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)2017 EPS Consensus Estimate: $2.91
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.59 | $0.63 | $0.61 |
| Q2 2017 | 1 | $0.71 | $0.71 | $0.71 |
| Q3 2017 | 2 | $0.81 | $0.86 | $0.84 |
| Q4 2017 | 1 | $0.75 | $0.75 | $0.75 |
(Data provided by Zacks Investment Research)
Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)| Most Recent Dividend: | 10/12/2017 |
| Annual Dividend: | $1.98 |
| Dividend Yield: | 4.83% |
| Dividend Growth: | -3.10% (3 Year Average) |
| Payout Ratio: | 198.00% (Trailing 12 Months of Earnings)
68.51% (Based on This Year's Estimates)
68.04% (Based on Next Year's Estimates)
|
Dividend History by Quarter for GlaxoSmithKline PLC (NYSE GSK)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/26/2017 | Quarterly | $0.49 | 4.88% | 8/9/2017 | 8/11/2017 | 10/12/2017 |
| 4/26/2017 | quarterly | $0.48 | 4.79% | 5/10/2017 | 5/12/2017 | 7/13/2017 |
| 2/8/2017 | quarterly | $0.57 | 5.76% | 2/22/2017 | 2/24/2017 | 4/13/2017 |
| 10/26/2016 | | $0.46 | | 11/2/2016 | 11/4/2016 | 1/12/2017 |
| 7/27/2016 | | $0.49 | | 8/10/2016 | 8/12/2016 | 10/13/2016 |
| 4/28/2016 | | $0.55 | | 5/11/2016 | 5/13/2016 | 7/14/2016 |
| 10/28/2015 | | $0.58 | | 11/10/2015 | 11/13/2015 | 1/14/2016 |
| 5/7/2015 | quarterly | $0.58 | 5.22% | 5/13/2015 | 5/15/2015 | 7/9/2015 |
| 2/5/2015 | quarterly | $0.70 | 6.05% | 2/18/2015 | 2/20/2015 | 4/9/2015 |
| 10/23/2014 | quarterly | $0.61 | 5.41% | 11/5/2014 | 11/7/2014 | 1/8/2015 |
| 7/24/2014 | quarterly | $0.65 | 5.18% | 8/6/2014 | 8/8/2014 | 10/2/2014 |
| 5/1/2014 | quarterly | $0.64 | 4.62% | 5/14/2014 | 5/16/2014 | 7/10/2014 |
| 2/5/2014 | | $0.75 | | 2/19/2014 | 2/21/2014 | 4/10/2014 |
| 2/6/2014 | quarterly | $0.75 | 5.73% | 2/19/2014 | 2/21/2014 | 4/10/2014 |
| 10/24/2013 | quarterly | $0.62 | 4.76% | 11/13/2013 | 11/15/2013 | 1/9/2014 |
| 7/25/2013 | quarterly | $0.55 | 4.27% | 8/7/2013 | 8/9/2013 | 10/3/2013 |
| 4/25/2013 | quarterly | $0.55 | 4.25% | 5/8/2013 | 5/10/2013 | 7/11/2013 |
| 2/7/2013 | quarterly | $0.07 | 0.61% | 2/20/2013 | 2/22/2013 | 4/11/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for GlaxoSmithKline PLC (NYSE:GSK)Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 9.28%
Insider Trades by Quarter for GlaxoSmithKline PLC (NYSE:GSK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/24/2016 | Plc Glaxosmithkline | Major Shareholder | Buy | 66,500 | $14.00 | $931,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for GlaxoSmithKline PLC (NYSE:GSK)
Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)
| Source: |
|
| Date | Headline |
|---|
 | What GlaxoSmithKline’s 3Q17 Performance Tells Us
finance.yahoo.com - October 19 at 1:09 AM |
 | Zacks Investment Research Upgrades GlaxoSmithKline PLC (GSK) to Buy
www.americanbankingnews.com - October 18 at 10:20 PM |
| Research Analysts Issue Forecasts for GlaxoSmithKline PLC's Q3 2017 Earnings (GSK)
www.americanbankingnews.com - October 18 at 9:06 AM |
| J P Morgan Chase & Co Reiterates "Neutral" Rating for GlaxoSmithKline PLC (GSK)
www.americanbankingnews.com - October 18 at 7:22 AM |
| GlaxoSmithKline PLC (GSK) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 18 at 5:56 AM |
 | Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada - Nasdaq
www.nasdaq.com - October 18 at 12:59 AM |
| T Rowe Price Equity Income Fund Buys DowDuPont Inc, American International Group Inc, ...
www.nasdaq.com - October 17 at 7:58 PM |
| Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
finance.yahoo.com - October 16 at 8:56 PM |
| Comparing GlaxoSmithKline PLC (GSK) & Its Rivals
www.americanbankingnews.com - October 12 at 6:12 AM |
 | Ebola vaccines from Merck, Glaxo show promise - MarketWatch
www.marketwatch.com - October 12 at 3:37 AM |
| [$$] Ebola Vaccines Show Promise in New Study
finance.yahoo.com - October 12 at 3:37 AM |
 | GlaxoSmithKline (GSK) Keeps Sell Recommendation - Investorplace.com
investorplace.com - October 7 at 11:09 PM |
 | GlaxoSmithKline plc is one of 10 top stocks for a Footsie starter portfolio
www.fool.co.uk - October 7 at 5:51 AM |
| Performance of GlaxoSmithKline’s Consumer Healthcare Segment
finance.yahoo.com - October 6 at 7:47 PM |
| Emergent Completes Acquisition of Anthrax Drug Raxibacumab
finance.yahoo.com - October 4 at 1:12 PM |
| Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
finance.yahoo.com - October 3 at 9:31 AM |
 | Supreme Court declines to hear GSK appeal in Paxil birth defect case - Reuters
www.reuters.com - October 2 at 6:50 PM |
| US judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline - Reuters
www.reuters.com - October 2 at 6:50 PM |
| U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline
finance.yahoo.com - October 2 at 6:50 PM |
| GSK: Lupus treatment Benlysta approved in Japan - MarketWatch
www.marketwatch.com - September 27 at 5:15 PM |
| Biotech's Boy Wonder Calls Alzheimer's Drug His 'Single Greatest Failure'
finance.yahoo.com - September 26 at 4:36 PM |
| Axovant Alzheimer's Drug Fails To Help Patients
finance.yahoo.com - September 26 at 11:26 AM |
 | Why I’d buy GlaxoSmithKline plc for its 5%+ dividend yield today
uk.finance.yahoo.com - September 25 at 10:29 AM |
| Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update
finance.yahoo.com - September 22 at 11:30 AM |
| J P Morgan Chase & Co Reiterates Neutral Rating for GlaxoSmithKline PLC (GSK)
www.americanbankingnews.com - September 21 at 6:20 AM |
| Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD ... - Nasdaq
www.nasdaq.com - September 20 at 5:21 AM |
| GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations
finance.yahoo.com - September 20 at 5:21 AM |
| GSK's new triple lung drug beats other modern inhalers in study
finance.yahoo.com - September 20 at 5:21 AM |
| GlaxoSmithKline's Trelegy Ellipta wins FDA OK
www.marketwatch.com - September 19 at 7:15 PM |
| [$$] Andrew Witty jumps into biotech venture capital
finance.yahoo.com - September 19 at 7:15 PM |
| Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD
finance.yahoo.com - September 19 at 7:15 PM |
| FDA OKs Glaxo's inhaler, first one to combine 3 medicines
finance.yahoo.com - September 19 at 7:15 PM |
| GlaxoSmithKline breathes easier as U.S. approves triple lung drug
finance.yahoo.com - September 19 at 4:49 AM |
| Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU - Nasdaq
www.nasdaq.com - September 18 at 6:45 PM |
| Interesting GSK Put And Call Options For May 2018 - Nasdaq
www.nasdaq.com - September 18 at 6:45 PM |
| Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
finance.yahoo.com - September 18 at 6:45 PM |
 | Innoviva (INVA) & GlaxoSmithKline Plc (GSK) Reports Positive Opinion from EMA CHMP for Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy
www.streetinsider.com - September 16 at 6:02 AM |
| France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus
finance.yahoo.com - September 15 at 7:54 PM |
| GSK, Innoviva: Trelegy Ellipta Gets CHMP Positive Opinion In Europe For COPD
www.nasdaq.com - September 15 at 5:58 AM |
| Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD
finance.yahoo.com - September 15 at 5:58 AM |
| GSK's three-in-one inhaler gets positive opinion from EU agency
finance.yahoo.com - September 15 at 5:58 AM |
 | One long-term growth stock I’d buy alongside GlaxoSmithKline plc
www.msn.com - September 14 at 7:55 PM |
| Glaxo shingles vaccine gets FDA panel backing - MarketWatch
www.marketwatch.com - September 14 at 3:34 AM |
| GlaxoSmithKline Plc : GSK-US: Dividend Analysis : August 11th, 2017 (record date) : By the numbers : September 12, 2017
finance.yahoo.com - September 12 at 8:07 PM |
 | 3 Dividend Superstars With Strong Growth Potential: GlaxoSmithKline, Pfizer, Sanofi
seekingalpha.com - September 12 at 8:00 AM |
| Why GlaxoSmithKline plc is the only pharma stock I’d ever own
uk.finance.yahoo.com - September 12 at 8:00 AM |
 | GSK Publishes Results Of Phase III Studies For Mepolizumab In COPD
www.rttnews.com - September 12 at 8:00 AM |
| When Should You Buy GlaxoSmithKline plc (LSE:GSK)?
finance.yahoo.com - September 12 at 8:00 AM |
| Innoviva (INVA) & GlaxoSmithKline (GSK) Announce Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet
www.streetinsider.com - September 11 at 7:45 PM |
| How Merck’s Gardasil and Other Human Vaccines Performed in 2Q17
finance.yahoo.com - September 11 at 7:45 PM |
GlaxoSmithKline PLC (GSK) Chart for Thursday, October, 19, 2017
